Fwd: Nonvisualization of a Sentinel Lymph Node on Lymphoscintigraphy Requiring Reinjection of Sulfur Colloid in a Patient With Breast Cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: Nonvisualization of a Sentinel Lymph Node on Lymphoscintigraphy Requiring Reinjection of Sulfur Colloid in a Patient With Breast Cancer.
To: mesothelioma77@gmail.com


[1]Clin Nucl Med. 2008 Jun; 33(6): 389-390
Teal CB, Brem RF, Rapelyea JA, Akin EA

PURPOSE:: The injection techniques and use of lymphoscintigraphy for sentinel lymph node (SLN) biopsy in breast cancer patients vary. Some do not advocate routine use of lymphoscintigraphy. The purpose of this case report is to illustrate when lymphoscintigraphy should be used. METHODS:: At our institution, we use periareolar intradermal injections of 0.6 mCi Tc-99m sulfur colloid followed by lymphoscintigraphy with reported identification rates greater than 99%. The only patient in our series who did not have a SLN identified had presented after excisional biopsy of an upper outer quadrant cancer. We report the case of another patient who presented after excision of an upper outer quadrant invasive ductal carcinoma and had no evidence of lymphatic drainage on lymphoscintigraphy after the periareolar injections of radioisotope. RESULTS:: Additional injections of 0.4 mCi Tc-99m sulfur colloid were performed lateral to the incision in the upper outer quadrant. On lymphoscintigraphy a SLN was visualized and was subsequently successfully identified intraoperatively. CONCLUSION:: This case report supports the value of lymphoscintigraphy for successful identification of a SLN in a patient with prior surgery. We therefore recommend imaging patients who have had prior breast surgery, particularly excisions in the upper outer quadrant.



___
Source: http://www.hubmed.org/display.cgi?uids=18496442
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Simultaneous thigh muscle metastasis from lung cancer and Escherichia coli gas producing myonecrosis.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: Simultaneous thigh muscle metastasis from lung cancer and Escherichia coli gas producing myonecrosis.
To: mesothelioma77@gmail.com


[1]Skeletal Radiol. 2008 May 22;
Martinez GE, Coursey CA, Dodd L, Martinez S

We present the case of a 41-year-old man with known large cell lung cancer who had undergone left pneumonectomy 7 months prior and who presented with a large intramuscular mass involving the posterior left thigh and upper calf. This thigh mass was ultimately surgically explored, and specimens yielded both Escherichia coli organisms and cells reflecting a skeletal muscle metastasis from the patient's known lung cancer. The patient was also found to have a rectal metastasis from his lung cancer. Intramuscular abscesses produced by gastrointestinal tract flora are a well-known presentation of colon cancer. To our knowledge, this is the first case report of the simultaneous occurrence of a skeletal muscle metastasis and an E. coli abscess in the same anatomic location. We believe the patient's rectal metastasis may have been the intermediate step in this process.



___
Source: http://www.hubmed.org/display.cgi?uids=18496688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Mammographic density using two computer-based methods in an isoflavone trial.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: Mammographic density using two computer-based methods in an isoflavone trial.
To: mesothelioma77@gmail.com


[1]Maturitas. 2008 May 19;
Kataoka M, Atkinson C, Warren R, Sala E, Day NE, Highnam R, Warsi I, Bingham SA

OBJECTIVES: Mammographic density is a useful biomarker of breast cancer risk. Computer-based methods can provide continuous data suitable for analysis. This study aimed to compare a semi-automated computer-assisted method (Cumulus) and a fully automated volumetric computer method (standard mammogram form (SMF)) for assessing mammographic density using data from a previously conducted randomised placebo-controlled trial of an isoflavone supplement. METHODS: Mammograms were obtained from participants in the intervention study. A total of 177 women completed the study. Baseline and follow-up mammograms were digitised and density was estimated using Cumulus (read by two readers) and SMF. Left-right correlation, changes in density over time, and difference between intervention and control groups were evaluated. Changes of density over time, and changes between intervention group and control group were examined using paired t-test and Student's t-test, respectively. RESULTS: Inter-reader correlation coefficient by Cumulus was 0.90 for dense area, and 0.86 for percentage density. Left-right correlation of percent density was lower in SMF than in Cumulus. Among all women, percentage density by Cumulus decreased significantly over time, but no change was seen for SMF percentage density. The intervention group showed marginally significant greater reduction of percent density by Cumulus compared to controls (p=0.04), but the difference became weak after adjustment for baseline percent density (p=0.06). No other measurement demonstrated significant difference between intervention and control groups. CONCLUSIONS: This comparison suggests that slightly different conclusions could be drawn from different methods used to assess breast density. The development of a more robust fully automated method is awaited.



___
Source: http://www.hubmed.org/display.cgi?uids=18495387
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: LA jury awards $9.7 million in asbestos suit (The Fresno Bee)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: LA jury awards $9.7 million in asbestos suit (The Fresno Bee)
To: mesothelioma77@gmail.com


A jury awarded $9.7 million to a Georgia man who said he developed chest cancer decades after he was exposed to asbestos while serving as a Navy machinist's mate aboard the USS Preble in Long Beach.

Fri, 23 May 2008 18:06:27 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11i2bk2ef/*http%3A//www.fresnobee.com/384/story/622490.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Endoscopic submucosal dissection for gastrointestinal neoplasms.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, May 22, 2008 at 5:14 PM
Subject: Endoscopic submucosal dissection for gastrointestinal neoplasms.
To: mesothelioma77@gmail.com


[1]World J Gastroenterol. 2008 May 21; 14(19): 2962-7
Kakushima N, Fujishiro M

Endoscopic submucosal dissection (ESD) is an advanced technique of therapeutic endoscopy for superficial gastrointestinal neoplasms. Three steps characterize it: injecting fluid into the submucosa to elevate the lesion, cutting the surrounding mucosa of the lesion, and dissecting the submucosa beneath the lesion. The ESD technique has rapidly permeated in Japan for treatment of early gastric cancer, due to its excellent results of en-bloc resection compared to endoscopic mucosal resection (EMR). Although there is still room for improvement to lessen its technical difficulty, ESD has recently been applied to esophageal and colorectal neoplasms. Favorable short-term results have been reported, but the application of ESD should be well considered by three aspects: (1) the possibility of nodal metastases of the lesion, (2) technical difficulty such as location, ulceration and operator's skill, and (3) organ characteristics.



___
Source: http://www.hubmed.org/display.cgi?uids=18494043
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, May 22, 2008 at 5:14 PM
Subject: Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion.
To: mesothelioma77@gmail.com


[1]PLoS ONE. 2008; 3(5): e2238
Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T

BACKGROUND: Estrogen is an established enhancer of breast cancer development, but less is known on its effect on local progression or metastasis. We studied the effect of estrogen receptor recruitment on actin cytoskeleton remodeling and breast cancer cell movement and invasion. Moreover, we characterized the signaling steps through which these actions are enacted. METHODOLOGY/PRINCIPAL FINDINGS: In estrogen receptor (ER) positive T47-D breast cancer cells ER activation with 17beta-estradiol induces rapid and dynamic actin cytoskeleton remodeling with the formation of specialized cell membrane structures like ruffles and pseudopodia. These effects depend on the rapid recruitment of the actin-binding protein moesin. Moesin activation by estradiol depends on the interaction of ERalpha with the G protein Galpha(13), which results in the recruitment of the small GTPase RhoA and in the subsequent activation of its downstream effector Rho-associated kinase-2 (ROCK-2). ROCK-2 is responsible for moesin phosphorylation. The Galpha(13)/RhoA/ROCK/moesin cascade is necessary for the cytoskeletal remodeling and for the enhancement of breast cancer cell horizontal migration and invasion of three-dimensional matrices induced by estrogen. In addition, human samples of normal breast tissue, fibroadenomas and invasive ductal carcinomas show that the expression of wild-type moesin as well as of its active form is deranged in cancers, with increased protein amounts and a loss of association with the cell membrane. CONCLUSIONS/SIGNIFICANCE: These results provide an original mechanism through which estrogen can facilitate breast cancer local and distant progression, identifying the extra-nuclear Galpha(13)/RhoA/ROCK/moesin signaling cascade as a target of ERalpha in breast cancer cells. This information helps to understand the effects of estrogen on breast cancer metastasis and may provide new targets for therapeutic interventions.



___
Source: http://www.hubmed.org/display.cgi?uids=18493596
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, May 22, 2008 at 5:14 PM
Subject: Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
To: mesothelioma77@gmail.com


[1]AJR Am J Roentgenol. 2008 Jun; 190(6): 1630-6
Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N

OBJECTIVE: Cancerous neovascular changes in histologically normal-appearing breast tissue have been shown to increase risk for local recurrence after breast-conserving therapy. However, the imaging characteristics of this tissue have not been well studied. We hypothesized that signal enhancement ratios from dynamic contrast-enhanced breast MRI could be used to analyze the contrast kinetics of microvasculature in breast stroma beyond the tumor margin and that this information can be developed to improve local treatment options. MATERIALS AND METHODS: Signal enhancement ratio analysis of nontumor breast stroma was performed on dynamic contrast-enhanced MRI scans of 42 patients who received neoadjuvant chemotherapy for invasive breast cancer performed before chemotherapy (scan 1) and after one cycle of chemotherapy (scan 2). Stromal signal enhancement ratio values were then correlated to several clinical parameters and to clinical outcome using univariate and multivariate analyses. Median follow-up for the group was 52.1 months. RESULTS: On univariate analysis, factors that were significantly associated (p

___
Source: http://www.hubmed.org/display.cgi?uids=18492917
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:29 AM
Subject: Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
To: mesothelioma77@gmail.com


[1]J Pathol. 2008 Apr 14;
Chen D, Chu CY, Chen CY, Yang HC, Chiang YY, Lin TY, Chiang IP, Chuang DY, Yu CC, Chow KC

Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) family of cytokines, and binds to the OSM receptor (OSMR) to inhibit cancer growth. Four forms of OSMR have been identified: leukemia inhibitory factor receptor (LIFR), OSMRbeta, short-form OSMR (OSMRs) and soluble OSMR (sOSMR). In this study, we examined the type and expression of OSMR in lung adenocarcinomas (LADCs). Expression of OSMR was determined by reverse transcription-polymerase chain reaction (RT-PCR), immunoblotting, immunohistochemistry and confocal immunofluorescent microscopy (CIM). Our results showed that, among the four forms of OSMR, OSMRs was mainly expressed in LADC, and expression level of OSMRs correlated with patient survival. CIM revealed that OSMRs was localized on the cell membrane of LADC cell lines in vitro. OSMRs acts as a decoy receptor by reducing the inhibitory effect of OSM on cell growth. Decrease in OSMRs expression by siRNA increased cell sensitivity to OSM, and ectopic expression of OSMRs reduced cell sensitivity to OSM. These results suggest that expression of OSMRs, which operates as a decoy receptor for OSM, is correlated with disease progression and adverse prognosis in patients with LADC. Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18491353
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:29 AM
Subject: Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.
To: mesothelioma77@gmail.com


[1]Prostate. 2008 May 19;
Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, Jones J, Shiry L, Allan G, Maddux BA, Goldfine ID

BACKGROUND: Nordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF-1 receptor (IGF-1R) in breast and other cancers, and concomitantly inhibits tumor growth both in cultured cells and animals. The current study evaluates the effect of NDGA on the androgen-stimulated growth of human prostate cancer cells. METHODS: LAPC-4 prostate cancer cells in tissue culture were androgen starved for 3 days, 1 nM dihydrotestosterone (DHT) and other androgens were then added for up to 7 days, and cell proliferation measured. IGF-1R protein expression was measured by Western blot, and IGF-1R mRNA expression by quantitative PCR. IGF-1R receptor kinase activation was measured by ELISA. RESULTS: After 7 days, LAPC-4 growth was doubled by 1 nM DHT. NDGA had a rapid effect to inhibit IGF-1R autophosphorylation induced by IGF-1. DHT increased the expression of IGF-1R protein and mRNA levels. Maximal IGF-1R protein levels were observed 3 days after the addition of androgen. In addition, NDGA, at 10 microM or less, inhibited DHT-induced proliferation in both cells grown in plates and cells grown in soft agar. Androgen receptor (AR) studies by FRET revealed that NDGA had no conformational effects on the AR in response to ligand. CONCLUSIONS: NDGA blocks the DHT-induced growth of LAPC-4 prostate cancer cells by several mechanisms including rapid inhibition of the IGF-1R kinase, and a dose-dependent inhibition of androgen stimulation of IGF-1R expression. Clinical studies of this agent will determine its efficacy in the setting of androgen-dependent prostate cancer. Prostate 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18491370
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:29 AM
Subject: Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
To: mesothelioma77@gmail.com


[1]Prostate. 2008 May 19;
Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD, Trock BJ, Partin AW, Walsh PC, Grönberg H, Xu J, Isaacs WB, Zheng SL

BACKGROUND: A strong cumulative effect of five genetic variants and family history on prostate cancer risk was recently reported in a Swedish population (CAPS). We carried out this study to confirm the finding in two U.S. study populations and perform a combined analysis to obtain a more stable estimate of the odds ratio (OR) for prostate cancer. METHODS: We evaluated three SNPs at 8q24 and one SNP each at 17q12 and 17q24.3 in two study populations in the U.S. The first was a hospital-based case-control study population at Johns Hopkins Hospital (JHH), including 1,563 prostate cancer patients and 576 control subjects. The second was the National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS) Initiative, including 1,172 prostate cancer patients and 1,157 control subjects. RESULTS: We confirmed a cumulative effect of five risk variants on prostate cancer risk. Based on a total of 5,628 cases and 3,514 controls from JHH, CGEMS, and CAPS, men who carry any combination of 1, 2, 3, and 4 or more of these five risk variants have an estimated OR (95% CI) of 1.41 (1.20-1.67), 1.88 (1.59-2.22), 2.36 (1.95-2.85), and 3.80 (2.77-5.22) for prostate cancer, respectively, compared to men who do not have any of these five risk variants. When family history was included, the cumulative effect was stronger. DISCUSSION: These results provide an important confirmation for the cumulative effect of five genetic risk variants on prostate cancer risk. The more stable OR estimates of the cumulative effect of these six risk factors are a major step toward individual risk characterization for this disease. Prostate (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18491292
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Nanotubes pose cancer risk (The Charlotte Observer)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:30 AM
Subject: Nanotubes pose cancer risk (The Charlotte Observer)
To: mesothelioma77@gmail.com


Certain types of carbon nanotubes -- microscopic graphite cylinders used in a small but growing number of Space Age applications -- could pose a similar cancer risk as asbestos if inhaled, scientists reported Tuesday. Researchers found that mice injected with nanotubes quickly developed the same biological damage associated with early exposure to asbestos fibers, a known carcinogen. The study ...

Wed, 21 May 2008 10:10:49 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11qaqic5l/*http%3A//www.charlotteobserver.com/162/story/633230.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc